Menu
← Oncology Approval Tracker
FDA DECISION ·
Fotivda
tivozanib · AVEO Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory advanced renal cell carcinoma after two or more prior systemic therapies.
LAMPGEN ANALYSIS
Why it matters
The VEGF receptor inhibitor was approved for later-line renal cell carcinoma.
What research teams should watch
Verify prior systemic treatment lines and document blood pressure monitoring and treatment holds.
PRIMARY RECORDS